BOT

2.04%

25.0¢ botanix pharmaceuticals ltd

The only person who had MRSA in the trial used the ointment and...

First 902 Last

Share
Profile

Follow
nebjin

104 Posts.

15

11/02/21

20:46

Post #: 50912248
Share

Originally posted by bigfella195: ↑

When the 1801 results were announced I was pleased that the primary endpoints had been achieved but was left with a few questions. I popped off an email to Botanix and this morning was able to get some answers. They could not have been any more open and forth coming, very appreciative. Thought I would share some insights:

- All 66 participants completed the trial. The participants were tested 3 times prior to the trial to determine if they had Staph Aureus. If they did not have a staph infection on the third test their data was not included and hence the percentages (A post yesterday clarified the calculations).

- There was no data collected at the end of day 5 as the trial was set up around the protocols of trials completed for other nasal decolonization products.

- 2 participants had MRSA, too few to be considered statistically significant. 1 in the vehicle group and 1 in the ointment group. The MRSA in the vehicle group was not eliminated, while the MRSA in the ointment group was successfully eliminated. Botanix had hoped there would be more MRSA cases.

- Side effects were really very mild, a little crustiness in some cases.

- The ASX no longer allow pharmaceutical companies to present comparisons with other company’s trials in announcements.

- The level of nasal staph was coded as eliminated, light, moderate or high. Data about staph levels in participants who were not classified as eliminated is still to come through.

- Participants who were recolognised by staph had there staph treated again and the staph was, in all cases, still susceptible suggesting no resistance development.

- In terms of recolognisation, staph is carried on many parts of the body and persistent carriers recolognize a lot. Other nasal decolonization studies gave participants full body chlorhexadine washes prior to the trial, something that was not done in Botanix’s trial.

- More data about the 1801 trial is still to come in.

-Matt Callaghan will be presenting remotely at a conference next week and hopefully will provide more data about the trial.

It is clear to me that Botanix genuinely believe the data is very good and compares well to competitors in the staph decolonization space, dialysis is one area they think this has some real potential.

My doubts about the results, based on some basic Google searches of other trials, were completely allayed. IMO Botanix is on to something and I’m not selling any time soon. Look forward to Matt’s presentation next week.

Expand

The only person who had MRSA in the trial used the ointment and it was eradicated. That's what we are talking about!

BOT Price at posting: 14.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 99 more messages in this thread...

First 902 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change 0.005(2.04%)		Mkt cap ! $393.7M

Open	High	Low	Value	Volume
24.5¢	25.5¢	24.5¢	$823.6K	3.305M

Buyers (Bids)

No.	Vol.	Price($)
7	292257	24.5¢

Sellers (Offers)

Price($)	Vol.	No.
25.0¢	67065	3

View Market Depth

No.	Vol.	Price($)
7	292257	0.245
7	397075	0.240
5	22593	0.235
7	210276	0.230
3	98685	0.225

Price($)	Vol.	No.
0.250	60000	1
0.255	326283	10
0.260	410720	15
0.265	438265	9
0.270	194345	5

Last trade - 16.10pm 03/05/2024 (20 minute delay)


Last 25.0¢		Change 0.005 ( 3.22 %)
Open	High	Low	Volume
24.5¢	25.5¢	24.5¢	1596484
Last updated 15.57pm 03/05/2024 ?

BOT (ASX) Chart

The only person who had MRSA in the trial used the ointment and...

Featured News

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Sold out signs go up for RIU Resources Roundup in Sydney

BPH Energy renews NT Bonaparte Basin permit

Provident Aurum's off-market bid sends Sihayo shares soaring

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

Dancing to that same 70s tune, China, and why I'm backing gold

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Infini Resources gearing up for UAV geophys survey over Portland Creek

Car EV-olution accelerates Oz into pole position

Buyers (Bids)

Sellers (Offers)

Featured News

The only person who had MRSA in the trial used the ointment and...

Featured News

Top Stories

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Sold out signs go up for RIU Resources Roundup in Sydney

BPH Energy renews NT Bonaparte Basin permit

Provident Aurum's off-market bid sends Sihayo shares soaring

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

Dancing to that same 70s tune, China, and why I'm backing gold

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Infini Resources gearing up for UAV geophys survey over Portland Creek

Car EV-olution accelerates Oz into pole position

Buyers (Bids)

Sellers (Offers)

Featured News